Spots Global Cancer Trial Database for The Combination Therapy With Ra-223 and Enzalutamide
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: The Combination Therapy With Ra-223 and Enzalutamide
Official Title: The Study of Combination Therapy With Radium-223 and Enzalutamide in Osaka City University
Study ID: NCT03305224
Interventions
Study Description
Brief Summary: This study is to evaluate preliminary efficacy of Ra-223 in combination with Enzalutamide in progressive CRPC patients with bone metastasis
Detailed Description:
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Osaka City University Graduate School of Medicine, Osaka, , Japan
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
